Faeth Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FTH research report →
Range $50 – $70
Price Chart
About the company
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
- CEO
- Anand Parikh
- IPO
- 2021
- Employees
- 29
- HQ
- Rockville, MD, US
Get TickerSpark's AI analysis on FTH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $203.14M
- P/E
- -0.06
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 1.21
- EV/EBITDA
- -0.89
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -153.55%
- ROIC
- -128.56%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-22,288,000
- Net Income
- $-21,085,000+30.1%
- EPS
- $-16.72+30.4%
- OCF Growth
- +17.1%
- FCF Growth
- +17.5%
- 52W High
- $42.14
- 52W Low
- $7.45
- 50D MA
- $22.10
- 200D MA
- $25.42
- Beta
- -0.30
- RSI (14)
- 23
- Avg Volume
- 500.25K
No earnings-call transcripts are available for FTH yet.
- Free Float
- 71.4%
- Shares Outstanding
- 25.78M
- Float Shares
- 18.40M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 57 ETFs
Biggest fund positions in FTH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 30, 26 | Parikh Anand Kiran | other | 100,000 |
| Oct 30, 26 | Parikh Anand Kiran | other | 100,000 |
| Oct 23, 26 | Schayowitz Adam | other | 25,000 |
| Oct 23, 26 | Schayowitz Adam | other | 0 |
| Sep 11, 26 | Vousden Karen H | other | 25,000 |
| Sep 11, 26 | Vousden Karen H | other | 0 |
| Jun 15, 26 | Khosla Ventures VI, L.P. | other | 0 |
| Jun 15, 26 | Khosla Ventures VI, L.P. | other | 0 |
| Jul 21, 26 | Craver Josiah | other | 30,824 |
| Jul 21, 26 | Parikh Anand Kiran | other | 398,018 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FTH coverage
Recent articles, reports, and earnings notes.
No research on FTH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FTH report →Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer
businesswire.com · Nov 16
Faeth Therapeutics to Participate in Upcoming November Investor Conferences
businesswire.com · Nov 11
Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer
businesswire.com · Nov 9
Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026
businesswire.com · Nov 6
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Nov 5
Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
businesswire.com · Nov 3
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
businesswire.com · Oct 27
Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
businesswire.com · Oct 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.